Showing results (271-280 of 367) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast CancerYen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Breast (Edinburgh, Scotland)|November 23, 2021
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)Jae Sik Kim, Kyubo Kim, Wonguen Jung, et al.
The Korean Journal of Internal Medicine|February 3, 2005
Use of complementary and alternative medicine among Korean cancer patientsMin Jae Kim, Sang Dae Lee, Duck Ryung Kim, et al.
JAMA Network Open|November 15, 2023
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialMasato Takahashi, Javier Cortés, Rebecca Dent, et al.
Frontiers in Oncology|March 25, 2026
Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Journal of Breast Cancer|November 20, 2023
Incidence of and Influencing Factors for Arm Lymphedema After Salvage Treatment for an Isolated Locoregional Recurrence of Breast CancerNalee Kim, Haeyoung Kim, Ji Hye Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast CancerPeter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
Radiation Oncology Journal|October 2, 2024
Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapyHyunki Park, Haeyoung Kim, Won Park, et al.
Pageof 37